티로신 키나아제 저해제(TKI) 시장 : 시장 규모, 점유율, 성장 분석 - 유형별, 용도별, 최종 사용자별, 유통 채널별, 지역별 산업 예측(2025-2032년)

Global Tyrosine Kinase Inhibitors Market size was valued at USD 36.9 billion in 2023 and is poised to grow from USD 39.0 billion in 2024 to USD 60.77 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The Tyrosine Kinase Inhibitors (TKIs) market is experiencing robust growth, propelled by the rising incidence of cancer and chronic illnesses that necessitate these pivotal therapies. By specifically targeting enzymes involved in cell signaling pathways, TKIs are vital in personalized medicine for treating diverse cancers like lung, breast, and leukemia. Recent advancements in molecular biology and drug development have led to the emergence of more effective, selective TKIs, enhancing patient outcomes and broadening available treatments. The market is bolstered by vigorous R&D efforts aimed at next-generation inhibitors to combat resistance and reduce side effects. However, challenges such as high costs and regulatory hurdles persist. Notably, trends like combination therapies with immunotherapies and innovative drug delivery systems are expected to further drive market expansion alongside growing global healthcare infrastructure.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tyrosine Kinase Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tyrosine Kinase Inhibitors Market Segments Analysis

Global Tyrosine Kinase Inhibitors Market is segmented by Type, Application, End Users, Distribution Channel and region. Based on Type, the market is segmented into BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors and Others. Based on Application, the market is segmented into Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer and Others. Based on End Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tyrosine Kinase Inhibitors Market

The Global Tyrosine Kinase Inhibitors market is primarily propelled by the alarming increase in cancer cases worldwide, especially in prevalent forms like lung cancer, breast cancer, and leukemia. Tyrosine Kinase Inhibitors (TKIs) provide targeted therapeutic strategies by disrupting specific enzymes that contribute to the proliferation of cancer cells, rendering them more effective and desirable alternatives to conventional chemotherapy methods. This rising interest in precision medicine, along with heightened public awareness and advancements in early cancer detection, is considerably widening the patient demographic that stands to benefit from the use of TKIs, further driving market growth.

Restraints in the Global Tyrosine Kinase Inhibitors Market

Although tyrosine kinase inhibitors (TKIs) offer significant clinical advantages, their high costs present a major barrier to accessibility, particularly in developing nations and for uninsured individuals. The overall expense encompasses not only the price of the medications themselves but also the necessary diagnostic tests and continual monitoring, which can put considerable pressure on healthcare systems and impede broad adoption. Financial limitations and challenges related to reimbursement may further stifle market growth, as both payers and healthcare providers look for more cost-effective treatment options. Consequently, these factors can restrict the overall reach and utilization of TKIs in various populations.

Market Trends of the Global Tyrosine Kinase Inhibitors Market

The Global Tyrosine Kinase Inhibitors (TKIs) market is witnessing a significant trend towards the integration of combination therapies with immunotherapy, particularly alongside checkpoint inhibitors. By synergistically enhancing the immune system's tumor-targeting capabilities while simultaneously inhibiting kinase-mediated tumor growth, these innovative treatment regimens are demonstrating enhanced efficacy in early clinical trials, characterized by improved response rates and prolonged progression-free survival. As research in this area expands, the paradigm shift towards these combination approaches is poised to redefine standard oncology treatment protocols, thereby unlocking substantial growth opportunities within the TKIs market and driving an evolution in cancer care strategies globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Tyrosine Kinase Inhibitors Market Size by Type & CAGR (2025-2032)

• Market Overview
• BCR-ABL Tyrosine Kinase Inhibitor
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
• Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
• Others

Global Tyrosine Kinase Inhibitors Market Size by Application & CAGR (2025-2032)

• Market Overview
• Chronic Myeloid Leukemia (CML)
• Lung Cancer
• Breast Cancer
• Others

Global Tyrosine Kinase Inhibitors Market Size by End Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Tyrosine Kinase Inhibitors Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Global Tyrosine Kinase Inhibitors Market Size & CAGR (2025-2032)

• North America (Type, Application, End Users, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, End Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascentage Pharma (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations